Last edition
News about "future clinical development"
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Future Clinical Development | 27/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members